Antimuscarinics may modestly reduce the rate and possibly the extent of levodopa absorption. One case describes levodopa toxicity, which occurred after the withdrawal of an antimuscarinic.
Concurrent use is of established benefit. The presence of a dopa-decarboxylase inhibitor would be expected to minimise the effects of any interaction. There is certainly no need to avoid concurrent use, but it would be prudent to be alert for any evidence of a reduced levodopa response if antimuscarinics are added, or for levodopa toxicity if they are withdrawn.
© 2006-2021 Last Updated On: 01/06/2021 (0)
Wait 20 seconds...!!!